New Strong Buy Stocks for March 4th

By Zacks Equity Research | March 04, 2026, 5:10 AM

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:

Orion Group ORN: This construction company, which provides services on and off the water primarily in the continental United States, Alaska, Canada and the Caribbean Basin, has seen the Zacks Consensus Estimate for its current year earnings increasing 15.8% over the last 60 days.

Orion Group Holdings, Inc. Price and Consensus

Orion Group Holdings, Inc. Price and Consensus

Orion Group Holdings, Inc. price-consensus-chart | Orion Group Holdings, Inc. Quote

Lam Research LRCX: This company which, supplies wafer fabrication equipment and services to the semiconductor industry, has seen the Zacks Consensus Estimate for its current year earnings increasing 8.9% over the last 60 days.

Lam Research Corporation Price and Consensus

Lam Research Corporation Price and Consensus

Lam Research Corporation price-consensus-chart | Lam Research Corporation Quote

Globus Medical GMED: This medical device company, that develops and commercializes healthcare solutions for patients with musculoskeletal disorders, has seen the Zacks Consensus Estimate for its current year earnings increasing 3.6% over the last 60 days.

Globus Medical, Inc. Price and Consensus

Globus Medical, Inc. Price and Consensus

Globus Medical, Inc. price-consensus-chart | Globus Medical, Inc. Quote

MYR Group MYRG: This leading specialty contractors, which serves the electrical infrastructure market throughout the United States and Canada who have the experience and expertise to complete electrical installations of any type and size, has seen the Zacks Consensus Estimate for its current year earnings increasing 3.4% over the last 60 day.

MYR Group, Inc. Price and Consensus

MYR Group, Inc. Price and Consensus

MYR Group, Inc. price-consensus-chart | MYR Group, Inc. Quote

Catalyst Pharmaceuticals CPRX: This commercial-stage biopharmaceutical company which, is focused on the development and commercialization of therapies targeting rare and difficult-to-treat diseases, has seen the Zacks Consensus Estimate for its current year earnings increasing 2% over the last 60 days.

Catalyst Pharmaceuticals, Inc. Price and Consensus

Catalyst Pharmaceuticals, Inc. Price and Consensus

Catalyst Pharmaceuticals, Inc. price-consensus-chart | Catalyst Pharmaceuticals, Inc. Quote

 

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Lam Research Corporation (LRCX): Free Stock Analysis Report
 
MYR Group, Inc. (MYRG): Free Stock Analysis Report
 
Orion Group Holdings, Inc. (ORN): Free Stock Analysis Report
 
Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis Report
 
Globus Medical, Inc. (GMED): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Latest News